Triana's platform aims to generate products that stabilize pre-existing or create de novo interactions between two proteins and alter the fate or functionality of the disease target. Molecular glues may allow for the pursuit of highly disease-relevant targets long considered undruggable or inadequately addressed by traditional drug discovery approaches.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/06/22 | $110,000,000 | Seed and Series A |
Atlas Venture Logos Capital Pfizer Venture Investments RA Capital Management Surveyor Capital | undisclosed |
